Table 2.
Main effect of CBD | Model | CBD Dose/concentration range | Route of administration | Species/Strain | Possible mechanism of action | References |
---|---|---|---|---|---|---|
Prevents NMDA receptor-induced excitoxicity | E17 cortical neurons culture | EC50 = 3.7 μM | In vitro | Wistar rat | Effect independent of cannabinoid receptors. | Hampson et al., 1998 |
↓Phosphorylated form of p38/MAP kinase, ↓Caspase 3 levels, and NFκ-b activation | β amyloid-induced neurotoxicity in PC12 cells | 10 μM | In vitro | PC12 cells | Antioxidant | Esposito et al., 2006 |
Prevented gliosis, neuronal death and ↑ hippocampal neurogenesis | Genetic model of Alzheimer's Disease | 10 mg/kg | 15 days | C57BL6 mice | PPARγ | Esposito et al., 2011 |
↓Aβ cell viability and ↓LPS (conditioned media) induced microglia activation | β amyloid -induced neuronal toxicity in neuroblastoma cells. LPS-induced microglial-activation | 10 μM | In vitro | Neuroblastoma (SH-SY5Y) cells/Microglial (BV-2) cells | Not determinated | Janefjord et al., 2014 |
Improved cell viability | Amyloid β -induced toxicity and tert-butyl hydroperoxide-induced oxidative stress | 0.01–10 μM | 15 min pre-incubation before Aβ or sAβ addition/ 24-h incubation for oxidative stress analysis | PC12 and Neuroblastoma (SH-SYS5) cells | Not determinated | Harvey et al., 2012 |
↓ Amyloid- β production | Amyloid β -induced neurotoxicity | 100 nM | 24 h | SHSY5Y (APP+) neurons | PPARγ | Scuderi et al., 2014 |
Reversed 3-nitropropionic acid—induced ↓ GABA contents, ↓ substance P, ↓ neuronal-specific enolase and superoxide dismutase(SOD)-2 | (10 mg/kg) 3-nitropropionic acid-induced) striatal lesions | 5 mg/kg | 5 days, i.p. | Sprague-Dawley rats | Independent of CB1, TRPV1 and A2A receptors | Sagredo et al., 2007 |
↓ Levels of IL-1beta, GFAP and iNOS | Amyloid β -induced neurotoxicity | 10 mg/kg | i.p. | C57BL6 mice | Not determinated | Esposito et al., 2007 |
Reduced dopamine depletion and ↑mRNA levels of SOD in the substantia nigra | 6-hydroxydopamine toxicity | 3 mg/kg | 14 days, i.p. | Sprague-Dawley rats | Antioxidant | Garcia-Arencibia et al., 2007 |
↓Cell death | H2O2-inducedoxidative stress in Oligodendrocyte progenitor cells | 1 μM | In vitro | Oligodendrocyte progenitor cells | Not determinated | Mecha et al., 2012 |
↓of carbonyl groups and prevents the decrease in BDNF expression | Amphetamine-induced oxidative stress | 60 mg/kg | 2 weeks, i.p. | Wistar rats | Not determinated | Valvassori et al., 2011 |
↓ NFκ-B, ↓ ICAM-1 and VACAM-1 | High glucose-induced mithocondrial superoxide generation | 4 μM | In vitro | Human coronary artery endothelial cells | Independent from CB1 and CB2 receptors | Rajesh et al., 2007 |
Prevented Aβ-induced cognitive deficits, ↓ microglia activation, ↓ IL-6 mRNA expression Inhibited NO generation and ATP-induced intracellular Ca2+ levels | Rat primary cortical cultures, N13 and BV-2 microglial cells Morris water maze | 10–1,000 nM | In vitro 3 weeks: first week treated daily; second and third weeks treated 3 times/week, i.p. | Rat primary cortical cultures, N13 and BV-2 microglial cells C57BL6 mice | Some of the in vitro effects were mediated by A2A, CB1, and CB2 receptors | Martín-Moreno et al., 2011 |
Blocked LPS-induced STAT1 activation | LPS-induced BV-2 activation | 10 μM | In vitro | BV-2 microglial cells | Not determinated | Kozela et al., 2010 |
↓Apoptosis; ↓Excitotoxicty and neuroinflamation | Newborn hypoxic-ischemic brain damage | 0.1–1,000 μM | Ex vivo | Brain slices from C57BL6 mice | CB2 and A2A receptors | Castillo et al., 2010 |
Protects against the reduction in tyrosine hydroxylase activity | 6-hydroxydopamine-induced toxicity in the striatum and substantia nigra | 3 mg/kg | 14 days, i.p. | Sprague-Dawley rats | Not determinated | Lastres-Becker et al., 2005 |
↑ Viable neurons and ↓ excitoxicity, oxidative stress, and inflammation | Newborn hypoxic-ischemic brain damage (HI) | 1 mg/kg | 30 min after HI, i.p. | Newborn pigs | CB2 and 5HT1A receptors | Pazos et al., 2013 |
Improve of cognition and motor activity. Restores BDNF levels | Encephalopathy (bile duct ligation) | 5 mg/kg | 28 days, i.p. | C57BL6 mice | 5HT1A | Magen et al., 2010 |
Improvments od liver function, normalizes 5-HT levels, and improves brain pathology | Encephalopathy (thioacetamide) | 5 mg/kg | Single dose | C57BL6 mice | 5HT-dependent mechanism | Avraham et al., 2011 |
Faciltates autophagic flux and decrease oxidative stress | Pilocarpine-Induced Seizure | 100 ng | Intracerebroventricular | Wistar rats | Induction of autophagy pathway | Hosseinzadeh et al., 2016 |
Suppresses the transcription proinflammatory genes | MOG35-55-specific T cell in the presence of spleen-derived antigen presenting cells | 5 μM | In vitro | MOG35-55- and APCs isolated from spleens of C57BL6 | Not determinated | Kozela et al., 2016 |
Attenuates TNF-α production and ↓ adenosine transport | murine microglia and RAW264.7 macrophages LPS-treated mice | 500 nM or 1 mg/kg | In vitro | Murine microglia | A2A adenosine receptor | Carrier et al., 2006 |
In vivo (1 h before LPS injection, i.p.) | RAW264.7 macrophages C57BL6 mice | |||||
Improves motor deficits in the chronic phase; ↓ microglial activation and Il-beta and TNF-α production | Viral model of multiple sclerosis | 5 mg/kg | 7 days, i.p | SJL/J mice | A2A adenosine receptor | Carrier et al., 2006 |
Normalizes synaptophyisin and caspase 3 expression | Brain damage induced by iron overload during neonatal period | Not informed | 14 day, i.p. | Wistar rats | Not determinated | da Silva et al., 2014 |
Prevented MPP-induced toxicity and induces neurite growth | MPP-induced toxicity in PC12 cells and SH-SY5Y | 1 μM | In vitro | PC12 and SH-SY5Y cells | TRKA | Santos et al., 2015 |
Prevents cognitive and anxiogenic effects, ↓ TNF-α and IL-6 ↑ BDNF levels | Murine model of cerebral Malaria | 30 mg/kg | 10 days, i.p. | C57BL6 mice | Not determinated | Campos et al., 2015 |
i.p., intra peritoneal; ↓, decreases; ↑, increases.